News | May 24, 2012

IsoRay’s GliaSite Approved for Sale in 31 European Countries

Significant Growth Expected as CE Mark Designation Clears Way for International Launch

May 24, 2012 — IsoRay Inc., a medical technology company in seed brachytherapy and medical radioisotope applications, announced that the GliaSite radiation therapy system, the world's only balloon catheter device used in the treatment of brain cancer, has earned the European CE Mark, allowing for immediate sale in 31 European countries. The system’s balloon catheter is a technology that allows physicians to treat more patients than before with brachytherapy or internal radiation, and provides important benefits over other radiation treatment options.

"This is a major event for IsoRay as it opens the door to revenue opportunities in international markets where our current distributor previously marketed GliaSite for its prior manufacturer. In addition, it allows us to pursue other distribution opportunities in countries not previously serviced. This completes the last requirement essential to initiate the international launch of our GliaSite radiation therapy system," said Dwight Babcock, chairman and CEO of IsoRay.

The GliaSite radiation therapy is being reintroduced to the market by IsoRay, which has exclusive worldwide rights to the system. IsoRay is also the manufacturer of cesium-131, which allows for the internal radiation treatment of many different cancers because of its combination of high energy and speed in giving off therapeutic radiation (9.7 day half-life).

IsoRay has already received a CE mark for its cesium-131 lung cancer sutures and mesh. Cesium-131 mesh brachytherapy gives physicians a viable treatment option for early-stage lung cancer patients who otherwise would have been inoperable because of limited pulmonary function or other health issues. With mesh brachytherapy, patients benefit from getting the most targeted radiation possible, which decreases the chance of the cancer recurring and decreases the amount of potential lung damage as compared to other available treatments. Some doctors report that they have found placing cesium-131 lung mesh over the surgical suture line reduces the risk of cancer recurrence in patients to 2 percent or less.

Babcock says this latest achievement comes on the heels of the company's reintroduction of the GliaSite radiation therapy system and introduction of cesium-131 sutures and mesh to the international medical community at the World Congress of Brachytherapy in May 2012.

For more information: www.isoray.com

Related Content

SpaceOAR Hydrogel Now Available in Japan
News | Patient Positioning Radiation Therapy | July 16, 2018
Augmenix K.K. announced that SpaceOAR hydrogel, a soft, implanted absorbable gel spacer is now available to all...
RaySearch Releases New Version of RayCare OIS
Technology | Oncology Information Management Systems (OIMS) | July 13, 2018
RaySearch has released RayCare 2A, the latest version of its flagship oncology information system (OIS). RayCare is...
Lack of Insurance Coverage Delaying Proton Therapy Clinical Trials
News | Proton Therapy | July 12, 2018
Randomized clinical trials are the gold standard of cancer research and can shed light on whether innovative, new...
Bruce Power Joins Forces With ITM to Supply Lutetium-177 for Cancer Therapy
News | Radiation Therapy | July 11, 2018
Canadian nuclear power company Bruce Power and German-based Isotope Technologies Garching (ITG) signed an agreement to...
MedStar Georgetown University Hospital Now Clinical With RayStation and Hyperscan
News | Treatment Planning | July 05, 2018
MedStar Georgetown University Hospital in Washington D.C., has begun patient treatments using the RayStation treatment...
Northern Centre for Cancer Care (NCCC)

Northern Centre for Cancer Care (NCCC).

Sponsored Content | Case Study | Radiation Therapy | July 05, 2018
Established in 2009, Northern Centre for Cancer Care (NCCC) is the largest center of its kind in the north of England....
Researcher Investigates Eliminating Radiation for HER2-Positive Breast Cancer
News | Radiation Therapy | July 02, 2018
Researchers at The University of Kansas Cancer Center have launched a clinical trial that eliminates radiation from the...
New Prostate Cancer Radiotherapy Technique Aims to Preserve Sexual Function
News | Radiation Therapy | June 18, 2018
A multicenter clinical trial being led by UT Southwestern physicians is testing a technique for sparing nerve bundles...
Elekta Unity High-Field MR-Linac Receives CE Mark
News | Image Guided Radiation Therapy (IGRT) | June 18, 2018
Elekta announced that its Elekta Unity magnetic resonance radiation therapy (MR/RT) system has received CE mark,...
Washington University in St. Louis Begins Clinical Treatments With ViewRay MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | June 14, 2018
June 14, 2018 — The Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in S
Overlay Init